JRCT ID: jRCTs031230672
Registered date:04/03/2024
Single-arm clinical trial of MOVICOL as a drug for preparation in children colonoscopy
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Preparation in children colonoscopy |
Date of first enrollment | 04/03/2024 |
Target sample size | 36 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | MOVICOL should be taken as two packets (120mL) per dose for 2-14 years old children and as three packets (180mL) per dose for over 12 years old, by dissolving one packet in 60 mL of water, tea, juice, or other solution. The timing and number of doses should be three times in total: in the afternoon and evening on the day before the colonoscopy, and in the morning on the day of the colonoscopy, and each dose should be taken within 2 hours. |
Outcome(s)
Primary Outcome | Bowe cleansing efficacy at the time of endoscopy (percentage of patients with Boston Bowel Preparation Scale (BBPS) >= 6). |
---|---|
Secondary Outcome | Cecal intubation rate. Acceptability Tolerability(questionnaire). Frequency and incidence of adverse events . |
Key inclusion & exclusion criteria
Age minimum | >= 2age old |
---|---|
Age maximum | <= 15age old |
Gender | Both |
Include criteria | 1.2 -15 years old at the time of obtaining consent. 2.Written informed consent obtained from patient and/or guardians. |
Exclude criteria | 1.Patients who have been on fasting for a long period of time and do not need pretreatment. 2.Patients requiring urgent colonoscopy. 3.Patients who are suspected of having bowel obstruction or ileus /intestinal perforation, toxic megacolon, acute abdomen, or stenotic lesions, and who are not eligible for regular preparation. 4.Patients with serious complications. 5.Patients with severe mental disorders or developmental disorders who have difficulty communicating. 6.Patients with a history of severe hypersensitivity to MOVICOL components. 7.Patients who are judged as ineligible for registration by attending doctors. |
Related Information
Primary Sponsor | Okamoto Kentaro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Yoshifumi Ito |
Address | 1-5-45, Yushima, Bunkyo-ku, Tokyo Tokyo Japan 113-8519 |
Telephone | +81-3-5803-5261 |
ito.srg2@tmd.ac.jp | |
Affiliation | Tokyo Medical and Dental University Hospital |
Scientific contact | |
Name | Kentaro Okamoto |
Address | 1-5-45, Yushima, Bunkyo-ku, Tokyo Tokyo Japan 113-8519 |
Telephone | +81-3-5803-5261 |
okasrg2@tmd.ac.jp | |
Affiliation | Tokyo Medical and Dental University Hospital |